The addition of pertuzumab to trastuzumab and chemotherapy does not significantly prolong overall survival (OS) in patients with HER2-positive (HER2+) metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC), according to the a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Spain.1
http://www.cancertherapyadvisor.com/esmo-2017/pertuzumab-not-prolong-survival-gastro-esophageal-cancer-treatment/article/687431/
Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers